Kailera Therapeutics, Inc. Common Stock(KLRA)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$13.27
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for KLRA

11/13/2026: KLRA (1-star) is currently NOT-A-BUY. Pass it for now.

Kailera Therapeutics is a clinical-stage biotechnology company specializing in next-generation therapies for obesity and metabolic disorders. The company's primary strength lies in its diversified pipeline of oral and injectable GLP-1 assets, anchored by its lead Phase 3 candidate, ribupatide. Its core growth story centers on capturing significant market share in the booming anti-obesity medication sector through differentiated delivery mechanisms. However, the company faces high risks, including the absence of commercial revenue, ongoing operational losses, and intense competition from entrenched industry giants. KLRA represents a high-risk, high-reward opportunity best suited for growth-oriented investors monitoring upcoming clinical trial readouts and regulatory milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveThe company offers high-beta exposure to the booming obesity drug market with multiple late-stage clinical catalysts.
Momentum investorStrong fit while signal remains positiveTrading volume and short-term price swings react sharply to clinical trial updates and broader biotech market sentiment.
Value investorWeak fitThe company generates zero revenues and trades entirely on clinical-stage pipeline potential rather than current earnings.
Dividend investorWeak fitAs a pre-commercial biotechnology firm, Kailera pays no dividends and retains all capital for drug development.
Low-risk investorWeak fitClinical trial binary outcomes and high stock volatility expose investors to substantial capital loss risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stocks experience sharp price swings reacting to regulatory news, clinical data, and market trends.
Valuation riskHighValuation depends entirely on future drug approvals rather than current financial fundamentals.
Competition risk (GLP-1 and obesity market dominance)HighThe company faces deep-pocketed incumbents like Eli Lilly and Novo Nordisk who control the current market.
Business qualityMedium / highThe pipeline is scientifically robust and licensed from a proven developer, but lacks commercial validation.
Dividend incomeLow / noneNo dividend distributions are expected for the foreseeable future.
Execution riskHighSuccess relies heavily on executing complex global Phase 3 clinical trials and securing regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.72B USD
Price to earnings Ratio -
1Y Target Price 43
Price to earnings Ratio -
1Y Target Price 43
Volume (30-day avg) 1.1M shares
Beta -
52 Weeks Range 9.76 - 28.23
Updated Date 11/15/2026
52 Weeks Range 9.76 - 28.23
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -4.16

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 0
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
KLRA receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
KLRA has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. Growth and ownership metrics are mixed: slightly negative earnings growth (+0.0%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
KLRA's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
KLRA's growth profile is soft, with the least-weak measure being revenue growth at +0.0% year over year. By comparison, while earnings growth (+0.0%, slightly negative) and free-cash-flow growth (+0.0%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 93.6% and approximately 45.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 9.25% supports management-shareholder alignment.

Top 5 Institutional Investors

Bain Capital Investors LLC 20.22%
Bain Capital Life Sciences Investors, LLC 17.39%
RTW INVESTMENTS, LLC 8.30%
Canada Pension Plan Investment Board 5.63%
Atlas Venture Life Science Advisors, LLC 3.98%

Unit Economics (Per $1K Revenue)

★★★★★
KLRA generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
KLRA has a relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical-Stage Therapeutics PipelineFuture commercialization of obesity and metabolic treatments including ribupatide and oral small molecules.The company currently makes no money and relies on investor capital while advancing drugs toward future commercial sales.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 830.98M
Price to Sales(TTM) -
Enterprise Value 830.98M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 129.85M
Shares Floating 58.68M
Shares Outstanding 129.85M
Shares Floating 58.68M
Percent Insiders 9.25
Percent Institutions 93.65

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.